Abstract
This chapter focuses on second-line therapy in inoperable pancreatic cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Burris HA 3rd, Moore MJ, Andersen J, et al. (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413
Pelzer U, Hempel C, Stieler J, et al. (2002) Oxaliplatin (OXA) in combination with high dose 5-FU (24 h)/folinic acid (FA) as salvage therapy in patients with gemzar-refractory advanced pancreatic cancer. Proc Am Soc Clin Oncol 21:A684
Oettle H, Pelzer U, Stieler J, et al. (2005) Oxaliplatin/folinic acid/5-fluorouracil [24 h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003). 2005 ASCO Annual Meeting Proceedings. J Clin Oncol [June 1 Suppl] 23:4031
Rothenberg ML, Moore MJ, Von Hoff DD, et al. (1996) A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 7:347–353
Sharma JJ, Razvillas B, Stephens CD, Hilsenbeck SG, Sharma A, Rothenberg ML (1997) Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer. Invest New Drugs 15:361–364
Ulrich-Pur H, Raderer M, Verena Kornek G, Schull B, Schmid K, Haider K, Kwasny W, Depisch D, Schneeweiss B, Lang F, Scheithauer W (2003) Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine pretreated advanced pancreatic cancer. Br J Cancer 88:1180–1184
Kozuch P, Grossbard ML, Barzdins A, Araneo M, Robin A, Frager D, Homel P, Marino J, DeGregorio P, Bruckner HW (2001) Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. Oncologist 6:488–495
Ng M, Norman AR, Cunningham D, et al. (2004) Phase II trial evaluating a 2 weekly regimen of irinotecan (IR) and 5-FU/leucovorin (LV) in patients with metastatic pancreatic cancer refractory to chemotherapy. 2004 ASCO Annual Meeting Proceedings. J Clin Oncol 22A:4229
Oettle H, Arnold D, Esser M, Huhn D, Riess H (2000) Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs 11:635–638
Aklilu M, Kindler HL, Nattam S, Brich A, Vokes EE (2004) A multicenter phase II study of arsenic trioxide (AT) in patients with advanced pancreatic cancer (PC) refractory to gemcitabine. 2004 ASCO Annual Meeting Proceedings. J Clin Oncol 22:A4114
Milella M, Gelibter A, Di Cosimo S, Bria E, Ruggeri EM, Carlini P, Malaguti P, Pellicciotta M, Terzoli E, Cognetti F, et al. (2004) Exploratory phase II study of celecoxib and infusional fluorouracil as second-line treatment for advanced pancreatic (PDAC) and biliary tree cancer (BTC). 2004 ASCO Annual Meeting Proceedings. J Clin Oncol 22:A4183
Tsavaris N, Kosmas C, Skopelitis H, Gouveris P, Kopterides P, Loukeris D, Sigala F, Zorbala-Sypsa A, Felekouras E, Papalambros E (2005) Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: a phase II study. Invest New Drugs 23:603
Demols A, Peeters M, Polus M, et al. (2006) Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer 27:481–485
Reni M, Pasetto L, Aprile G, et al. (2006) Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br J Cancer 27:785–791
Blaszkowsky LS, Kulke KH, Ryan DP, Clark JW, Meyerhardt J, Zhu AX, et al. (2005) A phase II study of erlotinib in combination with capecitabine in previously treated patients with metastatic pancreatic cancer. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol 23:4099
Klapdor R, Fenner C (2000) Irinotecan (CamptoR): efficacy as third/fourth line therapy in advanced pancreatic cancer. Anticancer Res 20:5209–5212
National Institutes of Health and the National Library of Medicine (2007) ClinicalTrials.gov. http://www.clinicaltrials.gov. Cited 2 Aug 2007
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Pelzer, U. (2008). Second-Line Chemotherapy in Advanced Pancreatic Cancer. In: Pancreatic Cancer. Recent Results in Cancer Research, vol 177. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-71279-4_8
Download citation
DOI: https://doi.org/10.1007/978-3-540-71279-4_8
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-71266-4
Online ISBN: 978-3-540-71279-4
eBook Packages: MedicineMedicine (R0)